Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use.
BACKGROUND
This study examines the links among diabetes, tardive dyskinesia (TD), and other extrapyramidal symptoms (EPS) in schizophrenia outpatients treated with typical and atypical antipsychotics.


OBJECTIVE
Using a retrospective chart review, we compared 30 schizophrenia patients with diabetes mellitus (DM) with 30 schizophrenia patients, matched for age and sex, with no DM. We compared prevalence and severity of parkinsonism, akathisia, TD, dystonia, and antipsychotic type (that is, typical vs atypical).


RESULTS
We found no statistically significant differences between the DM group and the non-DM group prevalence and severity of EPS, including TD.


CONCLUSIONS
We did not find DM and TD association to be significant in the era of atypical antipsychotics, possibly because of their antidyskinetic effect.
Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec. psychopharm.unit@mcgill.ca
Emmanuelle
E
Lévy
Howard C
HC
Margolese
Lawrence
L
Annable
Guy
G
Chouinard
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000453:epidemiology*; D004358:Drug Therapy / Q000592:standards*; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000453:epidemiology*; D004565:Electroconvulsive Therapy / Q000706:statistics & numerical data; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000175:diagnosis / Q000453:epidemiology*; D015995:Prevalence; D011595:Psychomotor Agitation / Q000175:diagnosis / Q000453:epidemiology*; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology* / Q000628:therapy; D012720:Severity of Illness Index
D014150:Antipsychotic Agents